AroCell AB (Sweden) Insiders
| AROC Stock | SEK 0.40 0.03 6.98% |
AroCell AB employs about 20 people. The company is managed by 8 executives with a total tenure of roughly 47 years, averaging almost 5.0 years of service per executive, having 2.5 employees per reported executive. Breaking down AroCell AB's management performance can provide insight into the firm performance.
| Gustav Sten Insider Chief Officer |
| BSc BSc Insider Chief Officer |
AroCell |
AroCell AB Management Team Effectiveness
The company has return on total asset (ROA) of (0.1585) % which means that it has lost $0.1585 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2635) %, meaning that it generated substantial loss on money invested by shareholders. AroCell AB's management efficiency ratios could be used to measure how well AroCell AB manages its routine affairs as well as how well it operates its assets and liabilities.AroCell AB Workforce Comparison
AroCell AB is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 398. AroCell AB holds roughly 20.0 in number of employees claiming about 5% of equities under Health Care industry.
The company has Profit Margin (PM) of (2.04) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.07) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.07. AroCell AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. AroCell AB Price Series Summation is a cross summation of AroCell AB price series and its benchmark/peer.
AroCell AB Notable Stakeholders
An AroCell AB stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AroCell AB often face trade-offs trying to please all of them. AroCell AB's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AroCell AB's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Gustav Sten | Chief Officer | Profile | |
| BSc BSc | Chief Officer | Profile | |
| Tina Yang | Chief Officer | Profile | |
| Marie Torstensson | Chief Officer | Profile | |
| Gunnar Wahlberg | Chief Rapid | Profile | |
| Maria Olofsson | Chief Officer | Profile | |
| Ellen Dittberner | Chief Officer | Profile | |
| Jonas Sderholm | Global Lead | Profile |
About AroCell AB Management Performance
The success or failure of an entity such as AroCell AB often depends on how effective the management is. AroCell AB management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AroCell management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AroCell management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
AroCell AB , a vitro diagnostics company, focuses on the monitoring of hematological malignancies, breast cancer, and other solid tumors. AroCell AB was founded in 2003 and is based in Uppsala, Sweden. AroCell AB is traded on Stockholm Stock Exchange in Sweden.
Please note, the imprecision that can be found in AroCell AB's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AroCell AB. Check AroCell AB's Beneish M Score to see the likelihood of AroCell AB's management manipulating its earnings.
AroCell AB Workforce Analysis
Traditionally, organizations such as AroCell AB use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AroCell AB within its industry.AroCell AB Manpower Efficiency
Return on AroCell AB Manpower
| Revenue Per Employee | 599.8K | |
| Revenue Per Executive | 1.5M | |
| Net Loss Per Employee | 2.5M | |
| Net Loss Per Executive | 6.3M | |
| Working Capital Per Employee | 2M | |
| Working Capital Per Executive | 5.1M |
Additional Tools for AroCell Stock Analysis
When running AroCell AB's price analysis, check to measure AroCell AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AroCell AB is operating at the current time. Most of AroCell AB's value examination focuses on studying past and present price action to predict the probability of AroCell AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AroCell AB's price. Additionally, you may evaluate how the addition of AroCell AB to your portfolios can decrease your overall portfolio volatility.